News
We send the latest information from SMC Laboratories.
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunct…
Drug efficacy studies using multiple mouse models to replicate human disease.
To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of…
The comparison of NASH-HCC and other HCC models
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related de…
Marvel Biosciences has published a press release regarding the MB-207 efficacy evaluation study for liver fibrosis provided by SMC
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ m…
STZ: Type 1 or Type 2 Diabetes?
When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does…
Lung fibrosis in COVID-19
COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damag…
ENYO Pharma announces positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks
ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a s…
New Partnership with cancer model search service Repositive, Inc.
SMC Laboratories, Inc. is pleased to announce a partnership with Repositive, Inc., a UK-based bespoke cancer m…
Amplia Therapeutics has publshed a pres releaes regarding the AMP945 and AMP886 efficacy evaluation study for NASH we have provied.
Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ …
Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in …